[ English | Bahasa Malaysia ] Today is 27th Jun 2022, 03:57 AM (Last updated: 22nd Jun 2022)

Text Red Text Black Text Blue Text Green Text Smaller Text Reset Text Larger

Publication Details
Year :


Journal :

Nadarajan VS, Phan CL, Ang CH, Liang KL, Gan GG, Bee PC and Zakaria Z (2011). Identification of copy number alterations by array comparative genomic hybrodization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate. International Journal of Hematology 93(4): 465-473

Abstract :

The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that accumulate during disease progression. We sought to identify such lesions in patients showing suboptimal response to IM by performing array-CGH analysis on 39 sequential samples from 15 CML patients. Seventy-four cumulative copy number alterations (CNAs) consisting of 35 losses and 39 gains were identified. Alterations flanking the ABL1 and BCR genes on chromosomes 9 and 22, respectively, were the most common identified lesions with 5 patients losing variable portions of 9q34.11 proximal to ABL1. Losses involving 1p36, 5q31, 17q25, Y and gains of 3q21, 8q24, 22q11, Xp11 were among other recurrent lesions identified. Aberrations were also observed in individual patients, involving regions containing known leukemia-associated genes; CDKN2A/2B, IKZF1, RB1, TLX1, AFF4. CML patients in late stages of their disease, harbor pre-existing and evolving sub-microscopic CNAs that may influence disease progression and IM response.




This site is best viewed on Firefox (24.0) with resolution higher than 1280 x 768 pixels.

Our Location


Located at Jalan Pahang, 50588 Kuala Lumpur, Malaysia. We operate from 8.00am - 5.00pm Monday - Friday. Click on the map image to launch Google Maps service.

Get in touch with us